. Relative Activity of Human FOXH1 Alleles In vitro synthesized mRNA encoding variant FOXH1 alleles were individually injected into zebrafish embryos together with an MO that interferes with endogenous zebrafish Foxh1 synthesis, and embryos were scored the next day according to their phenotypes ranging from wt, through classes I, II, III, and IV, to dead. These results were quantified and normalized as described in the Material and Methods. The x axis in the graphical display indicates the allele tested, and the y axis (wt-adjusted activity [WTAA] ) indicates the activity of the allele relative to wt FOXH1. The horizontal solid line indicates 100% wt activity. Circles, squares, and triangles represent the WTAA of single or averaged multiple experiments and vertical lines indicate the SEM associated with multiple experiments. Values used for the graph and the number of experiments and embryos used for each allele are shown in the accompanying Table S1 . Three groups of experiments are reported. Squares represent experiments that used 150 pg mRNA derived from vector OV; circles represent experiments that used 250 pg mRNA derived from vector OV; and triangles represent experiments that used 250 pg mRNA derived from vector NV. Differences between the OV and NV vectors are described in the Material and Methods. 
Statistical Analysis of

Error bars
By using both the number of experiments and WTAA in each mutation, error bars were generated as follows:
For a particular allele , represents the average of the WTAA through all the experiments, is the standard error and is the total of experiments. Error bars are presented in mutations which only. Estimated activities are indicated as black (100% or wt), orange (50%-99%), or red (less than 50% of normal).
a Sum of both Nodal alleles × 1/2. To facilitate comparisons of Nodal pathway activity between mouse and human, certain highly conservative assumptions were heuristically made to incorporate the concepts of functional redundancy. Therefore, gene products with similar function such as ligands (e.g., NODAL and GDF1) and coreceptors (e.g., CFC1 and TDGF1) are assumed to have additive effects whereas genes with no counterpart, such as FOXH1, are considered to influence net pathway flux multiplicatively. Each necessary component to the signaling pathway could have its independent effect on net pathway flux and not all such factors (e.g., Smad cofactors or receptor function and phosphorylation efficiency, etc.) have been included.
b Sum of both Gdf1 alleles × 1/2.
c Sum of Cfc1 and Tdgf1 alleles × 1/4. This is an overestimate because there is limited evidence that Cfc1 and Tdgf1 activities expression either overlaps or that the gene products are completely redundant in functional activity.
d Nodal activity × total EGF-CFC1 activity × Foxh1 activity × Smad2 activity. A hypothetical measure of how the protein products functionally interact to determine signaling strength. Does not measure the potential contributions of the differential expression, processing, receptor binding, or other unevaluated components of the total signaling system. For example, Smad3 can partially compensate for the lack of Smad2, and other Gdf factors, such as Gdf3, might similarly substitute for deficiencies of Gdf1.
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e Gdf1 activity × total EGF-CFC1 activity × Foxh1 activity × Smad2 activity. A hypothetical measure of how the protein products functionally interact to determine signaling strength.
f Sum of total Nodal and total Gdf signaling strength × 1/2. Applies to processes where Nodal and Gdf(s) are coexpressed and truly functionally redundant. Giving equal weight to Nodal and Gdf1 for certain processes is an oversimplification used for illustration purposes only.
g Indeed, recent studies suggest that Gdf1 possesses little intrinsic activity and instead forms heterodimers with Nodal to enhance the potency of the Nodal:Gdf1 complex. 12 Hence, Gdf factor(s) may act multiplicatively to augment Nodal's bioactivity instead of acting additively. Therefore, an alternative measure is to allow for an additional Gdf protein (such as Gdf3 and assumed to have full activity) to compensate for the absence of Gdf1 would be to add a % bioactive Gdf column to indicate this effect depends on Nodal. Therefore, Total TGFβ activity = Total Nodal × % bioactive Gdf. Note that now minor changes in either Nodal or Gdf proteins have an augmented effect on bioactivity.
h Foxh1 is considered the principal cotranscription factor; however, there must be factors that can compensate, otherwise Foxh1 nulls would completely phenocopy Nodal nulls. c Sum of CFC1 and TDGF11 alleles × 1/4. This is an overestimate because there is limited evidence that Cfc1 and Tdgf1 activities expression either overlaps or that the gene products are completely redundant in functional activity based on mouse studies.
d NODAL activity × total EGF-CFC1 activity × FOXH1 activity × SMAD2 activity. A hypothetical measure of how the protein products functionally interact to determine signaling strength. Does not measure the potential contributions of the differential expression, processing, receptor binding, or other unevaluated components of the total signaling system. e GDF1 activity × total EGF-CFC1 activity × FOXH1 activity × SMAD2 activity. A hypothetical measure of how the protein products functionally interact to determine signaling strength.
f Sum of NODAL and GDF signaling strength × 1/2. Applies to processes where Nodal and Gdf1 are coexpressed and truly functionally redundant. Giving equal weight to NODAL and GDF1 for certain processes is an oversimplification used for illustration purposes only. Indeed, as outlined in Table S3 , the effect of Gdf factors may (in most tissue fields) be to augment Nodal signaling by forming heterodimers with significantly increased activity. If this is true for the human proteins as well, then small detrimental changes to the intrinsic activities of either NODAL or GDF1 would have a substantial (and not additively compensated) effect on total signaling strength.
g Total NODAL × % bioactive GDF. Assumes that other GDF proteins compensate for loss of GDF1 (see Table S3 ).
